Cosciens Biopharma Valuation Multiples

Cosciens Biopharma is valued at $6M as of November 2026, a 0.4x revenue multiple. In the last fiscal year, Cosciens Biopharma revenue was $7M and Cosciens Biopharma EBITDA was ($9M).

Cosciens Biopharma Overview

About Cosciens Biopharma

Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.


Founded

1990

HQ

Canada

Employees

28

Financials (Last FY)

Revenue: $7M
EBITDA: ($9M)

EV

$3M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Cosciens Biopharma Financials

Cosciens Biopharma reported last fiscal year revenue of $7M and negative EBITDA of ($9M).

In the same fiscal year, Cosciens Biopharma generated $3M in gross profit, ($9M) in EBITDA losses, and had net loss of ($10M).


Cosciens Biopharma P&L

In the most recent fiscal year, Cosciens Biopharma reported revenue of $7M and EBITDA of ($9M).

Cosciens Biopharma is unprofitable as of last fiscal year, with gross margin of 35%, EBITDA margin of (124%), and net margin of (138%).

See analyst estimates for Cosciens Biopharma
Last FY2025202620272028
Revenue$7M$7M
Gross Profit$3M$3M
Gross Margin35%35%
EBITDA($9M)($9M)
EBITDA Margin(124%)(124%)
EBIT Margin(138%)(138%)
Net Profit($10M)($10M)
Net Margin(138%)(138%)
Net Debt($5M)-

Financial data powered by Morningstar, Inc.

Cosciens Biopharma Stock Performance

Cosciens Biopharma has current market cap of $6M, and enterprise value of $3M.

Market Cap Evolution


Cosciens Biopharma's stock price is $6.06.

Cosciens Biopharma has an EPS (earnings per share) of $-10.39.

See more trading valuation data for Cosciens Biopharma
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$3M$6M-0.2%---$-10.39

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Cosciens Biopharma Valuation Multiples

Cosciens Biopharma trades at 0.4x EV/Revenue multiple, and (0.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for Cosciens Biopharma

Cosciens Biopharma Financial Valuation Multiples

As of November 9, 2026, Cosciens Biopharma has market cap of $6M and EV of $3M.

Cosciens Biopharma has a P/E ratio of (0.6x).

Last FY2025202620272028
EV/Revenue0.4x0.4x
EV/EBITDA(0.3x)(0.3x)
EV/EBIT(0.3x)(0.3x)
EV/Gross Profit1.0x1.0x
P/E(0.6x)(0.6x)
EV/FCF(0.3x)(0.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Cosciens Biopharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Cosciens Biopharma Margins & Growth Rates

In the most recent fiscal year, Cosciens Biopharma reported gross margin of 35%, EBITDA margin of (124%), and net margin of (138%).

See estimated margins and future growth rates for Cosciens Biopharma

Cosciens Biopharma Margins

Last FY2025202720282029
Gross Margin35%35%
EBITDA Margin(124%)(124%)
EBIT Margin(138%)(138%)
Net Margin(138%)(138%)
FCF Margin(122%)(122%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Cosciens Biopharma Operational KPIs

Cosciens Biopharma's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.5M for the same period.

Access forward-looking KPIs for Cosciens Biopharma
Last FY2025202620272028
Revenue per Employee$0.3M-
Opex per Employee$0.5M-
G&A Expenses to Revenue31%31%
R&D Expenses to Revenue39%39%
Opex to Revenue174%174%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Cosciens Biopharma Competitors

Cosciens Biopharma competitors include Curis, Chosa Oncology, Wellgistics Health, Exicure, Acurx Pharmaceuticals, Longeveron, Bio Green Med Solution, Ensysce Biosciences, Medicofarma Biotech and Incanthera.

Most Cosciens Biopharma public comparables operate across Diagnostics & Genomics, Biopharmaceuticals, BioTech and DeepTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Curis$9M($6M)0.2x1.5x(0.4x)(0.1x)
Chosa Oncology-($599K)--(9.7x)-
Wellgistics Health$23M($93M)1.6x-(0.4x)-
Exicure-($5M)--(0.9x)-
Acurx Pharmaceuticals-($8M)----
Longeveron$1M($21M)1.6x0.9x(0.1x)-
Bio Green Med Solution$747K($3M)2.6x2.6x(0.6x)-
Ensysce Biosciences-($10M)-1.2x(0.6x)-

This data is available for Pro users. Sign up to see all Cosciens Biopharma competitors and their valuation data.

Start Free Trial

Acquisitions by Cosciens Biopharma

Cosciens Biopharma has acquired 3 companies to date.

Last acquisition by Cosciens Biopharma was on September 10th 2026. Cosciens Biopharma acquired Nualtis for $15M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Cosciens Biopharma

Nualtis
IntelGenX
Ceapro
Description
Nualtis is a pharmaceutical drug delivery company that develops oral thin film products for human and animal health. It was formerly known as IntelGenx and rebranded under the Nualtis name. The company owns proprietary film platforms, VersaFilm for human medicines and VetaFilm for veterinary use. It also provides research and development, analytical and manufacturing services, with capacity ranging from pilot scale to commercial production. Nualtis works with pharmaceutical partners, offering licensing opportunities and collaborative development of film-based products. The company is based in Montreal, Canada, and its roots date to 2003.
IntelGenx Corp. is a Longueuil-headquartered oral film drug delivery company. Its VersaFilm technology produces dissolvable films for therapies like buprenorphine and triptans, with FDA-approved products via partners like Purdue Pharma. The firm operates a 25,000 sq ft GMP facility for scale-up production. Founded in 1997, IntelGenx lists on TSX-Venture and partners with major pharma for R&D.
Ceapro is a biotechnology firm extracting active ingredients from oats and lupins for cosmeceuticals, nutraceuticals, and therapeutics. Headquartered in Edmonton, Alberta, Canada, since 1997, it produces beta-glucan, avenanthramides, oat peptides, and lupin peptides sold to personal care, cosmetics, and animal health sectors in the United States, Canada, Germany, and China. Ceapro advances Pressurized Gas eXpanded technology and CeaProve diabetes testing.
HQ CountryCanadaCanadaCanada
HQ City
Montreal
Montreal
Edmonton
Deal Date10 Sep 202610 Sep 202614 Dec 2023
Valuation$15M$15Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Cosciens Biopharma acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Cosciens Biopharma

When was Cosciens Biopharma founded?Cosciens Biopharma was founded in 1990.
Where is Cosciens Biopharma headquartered?Cosciens Biopharma is headquartered in Canada.
How many employees does Cosciens Biopharma have?As of today, Cosciens Biopharma has over 28 employees.
Who is the CEO of Cosciens Biopharma?Cosciens Biopharma's CEO is Gilles Gagnon.
Is Cosciens Biopharma publicly listed?Yes, Cosciens Biopharma is a public company listed on Toronto Stock Exchange.
What is the stock symbol of Cosciens Biopharma?Cosciens Biopharma trades under CSCI ticker.
When did Cosciens Biopharma go public?Cosciens Biopharma went public in 1992.
Who are competitors of Cosciens Biopharma?Cosciens Biopharma main competitors include Curis, Chosa Oncology, Wellgistics Health, Exicure, Acurx Pharmaceuticals, Longeveron, Bio Green Med Solution, Ensysce Biosciences, Medicofarma Biotech, Incanthera.
What is the current market cap of Cosciens Biopharma?Cosciens Biopharma's current market cap is $6M.
What is the current revenue of Cosciens Biopharma?Cosciens Biopharma's last fiscal year revenue is $7M.
What is the current EV/Revenue multiple of Cosciens Biopharma?Current revenue multiple of Cosciens Biopharma is 0.4x.
Is Cosciens Biopharma profitable?No, Cosciens Biopharma is not profitable.
How many companies Cosciens Biopharma has acquired to date?As of November 2026, Cosciens Biopharma has acquired 3 companies.
What was the largest acquisition by Cosciens Biopharma?$15M acquisition of Nualtis on 10th September 2026 was the largest M&A Cosciens Biopharma has done to date.
What companies Cosciens Biopharma acquired?Cosciens Biopharma acquired Nualtis, IntelGenX, and Ceapro.
In how many companies Cosciens Biopharma has invested to date?Cosciens Biopharma hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Cosciens Biopharma

Lists including Cosciens Biopharma

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial